How Zoetis stock has been performing

Zoetis (ZTS) has been trading under some pressure recently, with the share price seeing a 3% decline over the past day and a 5.8% decline over the past week.

Over a longer stretch, the stock has been comparatively steadier, with a marginal decline over the past month and a 3% total return gain over the past 3 months. The 1 year and multi year returns remain negative.

At a share price of $122.23, Zoetis has seen short term pressure with a 2.9% 1 day and 5.8% 7 day share price decline. The 1 year total shareholder return of 25.9% and 5 year total shareholder return of 15.9% remain weak, suggesting momentum has been fading rather than strengthening.

If this recent pullback has you thinking about where else to put your capital to work in healthcare, it could be a good time to scan 32 healthcare AI stocks as potential alternatives.

With Zoetis trading at $122.23, reportedly 42.2% below its estimated intrinsic value and under an average analyst price target of $151, investors now have to determine whether this represents genuine value or whether the market is already factoring in expectations for future growth.

Most Popular Narrative: 19.1% Undervalued

With Zoetis last closing at $122.23 against a widely followed fair value estimate of $151.00, the current price sits well below that narrative benchmark, putting the focus on what assumptions are doing the heavy lifting.

Ongoing innovation and accelerated R&D output, with expectations for a major new product approval in a key market every year over the next few years, positions Zoetis to expand addressable markets, launch higher-margin products, and protect market share, positively impacting organic revenue growth and net margins.

Curious what kind of revenue path and profit margins are baked into that fair value, and how rich a future P/E multiple it leans on? The full narrative spells out the earnings trajectory, valuation multiple and discount rate that need to line up for $151 to make sense.

Result: Fair Value of $151 (UNDERVALUED)

However, this story can change quickly if competitive pressure in key franchises or any stumble in the osteoarthritis pain pipeline affects the earnings path underlying that fair value.

Next Steps

With all this in mind, are you leaning bullish or cautious on Zoetis right now, and are you ready to weigh the trade off yourself? To see both sides and judge for yourself, take a look at the 5 key rewards and 1 important warning sign that sit behind this story.

Looking for more investment ideas?

If Zoetis has sharpened your thinking, do not stop here. Broadening your watchlist can help you spot opportunities you would otherwise miss.

• Target quality at a discount by scanning 47 high quality undervalued stocks that combine solid fundamentals with prices that sit below many investors' radars.
• Strengthen your portfolio's income stream by checking out 14 dividend fortresses offering robust yields that can help anchor total returns.
• Sleep a little easier by reviewing 73 resilient stocks with low risk scores designed for investors who want steadier businesses with more measured risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.